University of Maryland School of Medicine Orders a Bruker 950 MHz NMR System for Advanced Molecular Medicine & Structural Bio...
September 07 2010 - 7:00AM
Business Wire
Bruker Corporation (NASDAQ: BRKR) announces a major order from
the University of Maryland School of Medicine for its ultra-high
field AVANCE™ III 950 US2 NMR spectrometer. The 950 MHz
Nuclear Magnetic Resonance (NMR) magnet and spectrometer will help
University of Maryland researchers to unravel the mysteries of
molecules and develop new agents to treat cancer, AIDS and other
diseases. This will be only the second 950 MHz actively shielded
NMR magnet in North America.
The $7.9 million federal grant to fund the purchase of the
AVANCE III 950 US2 is among the largest of its kind ever awarded by
the National Center for Research Resources, which is part of the
National Institutes of Health. The funds were made available
through the American Recovery and Reinvestment Act.
The AVANCE III 950 US2 spectrometer delivers very high
sensitivity and broad spectral dispersion. Remarkably, the 950 US2
magnet features a 5 Gauss radial stray field of only 3.3 meters
(less than 11 feet), making it convenient to site within the
existing NMR lab at the University of Maryland. The AVANCE III
spectrometer is the fastest and highest performing NMR spectrometer
on the market. Its architecture delivers an unprecedented level of
digital control, speed, flexibility and exceptionally pure NMR
frequency generation. The AVANCE III second-generation (2G) digital
receiver (DR) technology delivers improvement in NMR detection,
enhancing the University of Maryland’s effort to further uncover
information about cancer and AIDS and the design of new drugs to
treat them.
The spectrometer will be housed in the NMR core facility at the
University of Maryland, Baltimore (UMB). Under a partnership, the
instrument will be used by researchers from UMB and two other
campuses – the University of Maryland, Baltimore County (UMBC) and
the University of Maryland, College Park.
“Being able to observe molecules at the atomic-level eliminates
a great deal of guessing when you’re conducting complicated
molecular experiments,” says David J. Weber, Ph.D., professor of
biochemistry and molecular biology at the University of Maryland
School of Medicine and director of the NMR core facility at UMB.
“We will have a much better ability to look at larger molecules and
protein complexes with this powerful magnet – it’s like working in
a room with the lights turned on.”
Dr. Weber’s laboratory is developing small-molecule inhibitors
geared to a family of calcium-binding proteins called S100
proteins, including one that is being tested in a clinical study as
a possible treatment for melanoma. Other cancer researchers are
studying ways to help repair the DNA in cells that have been
damaged by cancer.
Michael F. Summers, Ph.D., professor of chemistry and
biochemistry at UMBC, who will use the spectrometer to continue his
research into HIV/AIDS, commented: “Over the past several years, we
have been pushing the limits of our existing NMR facilities in our
studies of the molecular interactions that occur when HIV molecules
assemble in infected cells. The 950 MHz NMR instrument will allow
us to visualize the interactions that occur during the earliest
stages of assembly, when the protein molecules are first beginning
to bind and organize themselves on the virus' RNA genetic
material.”
About Bruker Corporation
Bruker Corporation is a leading provider of high-performance
scientific instruments and solutions for molecular and materials
research, as well as for industrial and applied analysis. For more
information about Bruker Corporation, please visit
http://www.bruker.com.
BRUKER CAUTIONARY STATEMENT
Any statements contained in this presentation that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including, but not limited to, risks and
uncertainties relating to adverse changes in conditions in the
global economy and volatility in the capital markets, the
integration of businesses we have acquired or may acquire in the
future, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products,
manufacturing, competition, dependence on collaborative partners
and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in
our filings with the Securities and Exchange Commission. These and
other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2009, our most
recent quarterly reports on Form 10-Q and our current reports on
Form 8-K. We expressly disclaim any intent or obligation to update
these forward-looking statements other than as required by law.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6418054&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024